Shanghai Bio-heart Biological Technology Co Ltd

Shanghai Bio-heart operates with a current ratio of 15.26, indicating strong short-term liquidity, but its debt-to-equity ratio of 0.41 suggests moderate leverage. The company holds CNY 92.28 million in cash and equivalents, while long-term debt stands at CNY 176.69 million, resulting in a net cash position of negative CNY 84.41 million. This liquidity profile is consistent with a medium liquidity risk rating. Profitability metrics are weak, with a return on equity of -16.11% and a return on assets of -8.41%. These figures fall significantly below the industry median for medical device firms, which typically report positive ROE and ROA in the 5-10% range. The company reported a net loss of CNY 70.05 million in the latest period, driven by an operating loss of CNY 85.79 million. The company's revenue is concentrated in its domestic market, with no disclosed international operations. Its product portfolio includes three core offerings: the Bioheart bioresorbable scaffold system, the Iberis second-generation renal denervation system, and drug-coated balloons. No segment-specific revenue breakdown is available, but the lack of geographic diversification increases exposure to regulatory and reimbursement shifts in China. Growth remains unproven, with a single year of financial data available. The company reported revenue of CNY 44.93 million, but no prior-year comparison is provided. Given the high R&D intensity of the medical device industry, the absence of positive operating cash flow or revenue growth raises questions about long-term scalability. Risk factors include a negative net cash position and a lack of profitability. The company has not issued shares in the past 12 months, and dilution risk is currently rated as low. However, the need for continued R&D investment and regulatory approvals could necessitate future capital raises, which may dilute existing shareholders. Recent filings and transcripts are not available in the input data. The company's 10-K or equivalent disclosures would be necessary to assess management commentary, clinical trial progress, and regulatory milestones. Investors should monitor upcoming product approvals and reimbursement decisions in China.